Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 90833 

Additionally, VA is looking to expand 

the list of authorized forms for use due 

to ongoing needs related to the 

pandemic. This collection of 

information provides a more thorough 

and complete appraisal of prospective 

VA-guaranteed properties ensuring that 

mortgages are acceptable for VA 

guarantee and thereby protect the 

interest of VA, taxpayers, and the 

Veterans Housing Benefit Program 

Fund. Policies and procedures for 

governing the VA appraisal program are 

set forth in Chapter 36, Title 38 of the 

CFR. 

An agency may not conduct or 

sponsor, and a person is not required to 

respond to a collection of information 

unless it displays a currently valid OMB 

control number. 

The Federal Register Notice with a 

60-day comment period soliciting 

comments on this collection of 

information was published at 89 FR 

73508, September 10, 2024. 

Affected Public: Individuals or 

Households. 

Estimated Annual Burden: 10,833. 

Estimated Average Burden per 

Respondent: 1 minute. 

Frequency of Response: One time. 

Estimated Number of Respondents: 

650,000. 

(Authority: 44 U.S.C. 3501 et seq.) 

Maribel Aponte, 

VA PRA Clearance Officer, Office of 

Enterprise and Integration, Data Governance 

Analytics, Department of Veterans Affairs. 

[FR Doc. 2024–26803 Filed 11–15–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Findings of Research MisconductC 

AGENCY: Department of Veterans Affairs. 

ACTION: Notice. 

SUMMARY: The Department of Veterans 

Affairs (VA), gives notice, pursuant to 

Veterans Health Administration (VHA) 

Directive 1058.02 ‘‘Research 

Misconduct’’ section 8.l, that the 

Department has made findings of 

research misconduct against Alan 

Lichtenstein, M.D. (‘‘Respondent’’), a 

former staff physician at the VA Greater 

Los Angeles Healthcare System, Los 

Angeles, CA. The Respondent did not 

appeal the findings or corrective actions 

against him. 

FOR FURTHER INFORMATION CONTACT: 

Shara Kabak, Research Misconduct 

Officer, Office of Research Oversight 

(10RO), 810 Vermont Avenue NW, 

Washington, DC 20420, (202) 632–7620 

(this is not a toll-free number). 

SUPPLEMENTARY INFORMATION: VA has 

made final findings of research 

misconduct against Alan Lichtenstein, 

M.D. (‘‘Respondent’’), a former staff 

physician at the VA Greater Los Angeles 

Healthcare System in Los Angeles, CA. 

Based on the recommended findings 

of a joint investigation conducted by VA 

Greater Los Angeles Healthcare System 

and University of California, Los 

Angeles School of Medicine, the 

Department found that the Respondent 

engaged in research misconduct by 

recklessly falsifying data included in at 

least ten of the following thirteen 

published papers: 

• DEPTOR is linked to a TORC1-p21 

survival proliferation pathway in 

multiple myeloma. Genes & Cancer. 

2014 Nov;5(11–12):407–19. doi: 

10.18632/genesandcancer.44 (hereafter, 

‘‘Genes Cancer 2014’’). 

• Cytotoxic properties of a DEPTORmTOR inhibitor in multiple myeloma 

cells. Cancer Research. 2016 Oct 

1;76(19):5822–5831. doi: 10.1158/0008– 

5472. CAN–16–1019 (hereafter, ‘‘Cancer 

Res. 2016’’). 

• Interleukin-6 activates 

phosphoinositol-3 kinase in multiple 

myeloma tumor cells by signaling 

through RAS-dependent and, separately, 

through p85-dependent pathways. 

Oncogene. 2004 Apr 22;23(19):3368–75. 

doi: 10.1038/sj.onc.1207459 (hereafter, 

‘‘Oncogene 2004’’). 

• MNK1-induced eIF–4E 

phosphorylation in myeloma cells: a 

pathway mediating IL–6-induced 

expansion and expression of genes 

involved in metabolic and proteotoxic 

responses. PLoS One. 2014 Apr 

8;9(4):e94011. doi: 10.1371/ 

journal.pone.0094011 (hereafter, ‘‘PLoS 

One 2014’’). Retraction in: PLoS One. 

2023 Sep 8;18(9):e0291491. doi: 

10.1371/journal.pone.0291491. 

• Mammalian target of rapamycin 

inhibitors activate the AKT kinase in 

multiple myeloma cells by up-regulating 

the insulin-like growth factor receptor/ 

insulin receptor substrate-1/ 

phosphatidylinositol 3-kinase cascade. 

Molecular Cancer Therapeutics. 2005 

Oct;4(10):1533–40. doi: 10.1158/1535– 

7163.MCT–05–0068 (hereafter, ‘‘Mol 

Cancer Ther. 2005’’). 

• Inhibition of SAPK2/p38 enhances 

sensitivity to mTORC1 inhibition by 

blocking IRES-mediated translation 

initiation in glioblastoma. Molecular 

Cancer Therapeutics. 2011 10:2244– 

2256 Dec;10(12):2244–56. doi: 10.1158/ 

1535–7163.MCT–11–0478 (hereafter, 

‘‘Mol Cancer Ther. 2011’’). 

• Specific blockade of Rictor-mTOR 

association inhibits mTORC2 activity 

and is cytotoxic in glioblastoma. PLoS 

One. 2017; Apr 28;12(4):e0176599. doi: 

10.1371/journal.pone.0176599 

(hereafter, ‘‘PLoS One 2017’’). 

Correction in: PLoS One. 2019 Feb 

6;14(2):e0212160. doi: 10.1371/ 

journal.pone.0212160. Retraction in: 

PLoS One. 2023 Sep 8;18(9):e0291490. 

doi: 10.1371/journal.pone.0291490. 

• MNK kinases facilitate c-myc IRES 

activity in rapamycin-treated multiple 

myeloma. Oncogene. 2013 Jan 

10;32(2):190–7. doi: 10.1038/ 

onc.2012.43 (hereafter, ‘‘Oncogene 

2013’’). Expression of Concern in: 

Oncogene. 2023 Oct;42(41):3088. doi: 

10.1038/s41388–023–02818–z. 

• The PP242 mammalian target of 

rapamycin (mTOR) inhibitor activates 

extracellular signal-regulated kinase 

(ERK) in multiple myeloma cells via a 

target of rapamycin complex 1 (TORC1)/ 

eukaryotic translation initiation factor 

4E (eIF–4E)/RAF pathway and 

activation is a mechanism of resistance. 

Journal of Biological Chemistry. 2012 

Jun 22;287(26):21796–805. doi: 10.1074/ 

jbc.M111.304626 (hereafter, ‘‘J Biol 

Chem. 2012’’). 

• Therapeutic potential of targeting 

IRES-dependent c-myc translation in 

multiple myeloma cells during ER 

stress. Oncogene. 2016 Feb 

25;35(8):1015–24. doi: 10.1038/ 

onc.2015.156 (hereafter, ‘‘Oncogene 

2016’’). Retraction in: Oncogene. 2023 

Sep;42(40):3016. doi: 10.1038/s41388– 

023–02820–5. 

• SGK kinase activity in multiple 

myeloma cells protects against ER stress 

apoptosis via a SEK-dependent 

mechanism. Molecular Cancer 

Research. 2016 Apr;14(4):397–407. doi: 

10.1158/1541–7786.MCR–15–0422 

(hereafter, ‘‘Mol Cancer Res. 2016’’). 

• A novel therapeutic induces 

DEPTOR degradation in multiple 

myeloma cells with resulting tumor 

cytotoxicity. Molecular Cancer 

Therapeutics. 2019 Oct;18(10):1822– 

1831. doi: 10.1158/1535–7163.MCT–19– 

0115 (hereafter, ‘‘Mol Cancer Ther. 

2019’’). 

• Downstream effectors of oncogenic 

ras in multiple myeloma cells. Blood. 

2003 Apr 15;101(8):3126–35. doi: 

10.1182/blood–2002–08–2640 

(hereafter, ‘‘Blood 2003’’). 

Specifically, the Department found 

that the Respondent recklessly 

committed research misconduct by 

reusing the same Western blot or kinase 

assay image to falsely represent the 

results related to the following pairs of 

experiments such that at least one of the 

sets of images in each of the pairs listed 

below is inaccurate: 

• p-4E–BP1–T37/46, p–4E–BP1–S65 

and Tubulin expression in Figure 3B of 

Genes Cancer 2014 and Figure 1F of 

Cancer Res. 2016. 


lotter on DSK11XQN23PROD with NOTICES1
90834 Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 

• P–AKT–S473 expression in Figure 

3C in Genes Cancer 2014 and lanes 1– 

4 of DEPTOR expression in Figure 3C of 

Cancer Res. 2016 with resizing. 

• Lanes 7–9 of p70S6K1 expression in 

Figure 1A of Genes Cancer 2014 and 

DEPTOR expression in Figure 4C of 

Cancer Res. 2016. 

• STAT3 associated kinase activity in 

Figure 4A and lanes 1–4 of p110 mu 

associated kinase activity in Figure 5B 

of Oncogene 2004. 

• Lanes 7–8 of ACTIN expression in 

Figure 1A and lanes 7–8 of ACTIN 

expression in Figure 1C of PLoS One 

2014. 

• Lanes 3–4 of P–MNK and T–MNK 

expression in Figure 1C of PloS One 

2014 and lanes 1–2 of FKHD–P and 

FKHD–T expression (top panels) in 

Figure 1B of Mol Cancer Ther. 2005. 

• Lanes 4–8 of P–AKT (S473) and 

actin expression in Figure 2A of Mol 

Cancer Ther. 2011 and AKT and S6K 

expression in Figure 1F of PloS One 

2017 with a 180 degree rotation of the 

P–AKT/AKT panels. 

• Lanes 1–2 of T–HSP27 expression 

and lanes 4–5 of GAPDH expression in 

Figure 2B of Oncogene 2013. 

• Lanes 1–3 of p–erk and lanes 2–4 of 

t-erk expression in Figure 3B and lanes 

1–3 of erk(T202/Y204) and erk 

expression in Figure 4A of J Biol Chem. 

2012. 

• a-tubulin expression in Figure 4D 

and 4E of Genes Cancer 2014. 

• C-myc expression in Figure 1B and 

lanes 1–4 of T-p70 expression in Figure 

1E of Oncogene 2016. 

• T–4E–BP1 (a, b and g 

phosphorylated forms) expression 

(middle panel) and lanes 1–4 of T–4E– 

BP (a, b and g phosphorylated forms) 

expression (right panel) of 

Supplemental Figure 2A of Oncogene 

2016. 

• T–S6 expression and C–myc 

expression in Figure 1F of Oncogene 

2016. 

• Lanes 2–5 of MNK–P and MNK–T 

expression (left panel) in Figure 3A and 

ERK–T and Hsp–27–T expression in 

Figure 4A of Oncogene 2016. 

• MNK1, MNK2 and GAPDH 

expression in Figure 3E of Oncogene 

2016 and MNK1, MNK2 and GAPDH 

expression in Figure 3A of PloS One 

2014. 

• ire–1–total expression (right panel) 

in Figure 5B of Mol Cancer Res. 2016 

and mTor expression in Figure 8A of 

Genes Cancer 2014 with resizing. 

• The right panel of ACTIN 

expression in Figure 2A and the right 

panel of ACTIN expression in Figure 2g 

of Mol Cancer Ther. 2019. 

• Lanes 1–6 of DEPTOR and mTOR 

expression in Figure 1A of Genes 

Cancer 2014 and DEPTOR and mTor 

expression in Figure 6A of Mol Cancer 

Ther. 2019. 

• IRS–1 expression in lanes 4–5 and 

lanes 8–9 in Figure 6B of Mol Cancer 

Ther. 2005. 

• AKT expression (bottom panel) in 

Figure 1Aand lanes 7–9 of IRS–1 

expression in Figure 6B of Mol Cancer 

Ther. 2005. 

• Lanes 4–6 of IGF–R expression and 

lanes 4–6 of FLAG expression in Figure 

5B of Mol Cancer Ther. 2005 with a 180- 

degree rotation. 

• Lanes 2–3 of AKT–T expression 

(4th panel) in and lanes 1–2 of AKT–T 

expression (6th panel) in Figure 1C of 

Mol Cancer Ther. 2005. 

• Lanes 1–2 of AKT–P expression 

(top panel) and lanes 1–2 of AKT–P 

expression (5th panel) in Figure 1E of 

Mol Cancer Ther. 2005. 

• Lanes 1–3 and lanes 5–7 of FKH–T 

expression in Figure 3C of Blood 2003. 

• Lane 1 of p70 expression and 

Ser411 expression in Figure 4B and lane 

4 of Ser411 expression and lanes 1–2 of 

Ser411 expression in Figure 4c of Blood 

2003. 

• Lanes 1 and 3 of ERK–P expression 

and lanes 2 and 4 of ERK–T expression 

in Figure 2C of Blood 2003. 

Based on these findings of research 

misconduct, which the Respondent did 

not appeal, the Department has imposed 

the following corrective actions: 

(1) Prohibition from conducting VA 

research for at least 2 years; 

(2) Notification to the relevant 

journals of the research misconduct 

findings. 

Signing Authority 

Denis McDonough, Secretary of 

Veterans Affairs, signed and approved 

this document on November 12, 2024, 

and authorized the undersigned to sign 

and submit the document to the Office 

of the Federal Register for publication 

electronically as an official document of 

the Department of Veterans Affairs. 

Jeffrey M. Martin, 

Assistant Director, Office of Regulation Policy 

& Management, Office of General Counsel, 

Department of Veterans Affairs. 

[FR Doc. 2024–26756 Filed 11–15–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

[OMB Control No. 2900–0012] 

Agency Information Collection Activity 

Under OMB Review: Application for 

Cash Surrender or Policy Loan and 

Application for Cash Surrender 

(Docusign) 

AGENCY: Veterans Benefits 

Administration, Department of Veterans 

Affairs. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act (PRA) of 

1995, this notice announces that the 

Veterans Benefits Administration, 

Department of Veterans Affairs, will 

submit the collection of information 

abstracted below to the Office of 

Management and Budget (OMB) for 

review and comment. The PRA 

submission describes the nature of the 

information collection and its expected 

cost and burden, and it includes the 

actual data collection instrument. 

DATES: Comments and 

recommendations for the proposed 

information collection should be sent by 

December 18, 2024. 

ADDRESSES: To submit comments and 

recommendations for the proposed 

information collection, please type the 

following link into your browser: 

www.reginfo.gov/public/do/PRAMain, 

select ‘‘Currently under Review—Open 

for Public Comments’’, then search the 

list for the information collection by 

Title or ‘‘OMB Control No. 2900–0012.’’ 

FOR FURTHER INFORMATION CONTACT: VA 

PRA information: Maribel Aponte, (202) 

461–8900, vacopaperworkreduact@

va.gov. 

SUPPLEMENTARY INFORMATION: 

Title: Application for Cash Surrender 

or Policy Loan (VA Form 29–1546). 

Application for Cash Surrender (VA 

Form 29–1546e—DocuSign). 

OMB Control Number: 2900–0012— 

https://www.reginfo.gov/public/do/ 

PRASearch. 

Type of Review: Extension without 

change of a currently approved 

collection. 

Abstract: The Application for Cash 

Surrender or Policy Loan solicits 

information needed from Veterans to 

apply for cash surrender value or policy 

loan on his/her insurance. The VA Form 

29–1546e has been added to this 

collection. This is an electronic version 

of the 29–1546 but is for cash surrender 

only. This form was created so Veterans 

can apply for a cash surrender of their 

policy online. This will not affect the 

number of respondents but will make it 


lotter on DSK11XQN23PROD with NOTICES1